Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 2/5 criteria met.
- ❌ Price trend failed
- ✅ Growth passed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2024 → 2025: 613.33%
Price change 2025 → 2026: -99.90%
Price change 2026 (year to date): -99.90%
Financial growth
Revenue CAGR (5 years): 26.41%
Earnings CAGR (5 years): 88.96%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.11
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.01
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 99.91% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="HAO" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Haoxi Health Technology Limited | – | 0.12 | +33.7 % | 🔒 |
| Digitalbox plc | – | 0.00 | +1.7 % | – |
| Inuvo, Inc. | – | 0.40 | +3.8 % | – |
| Nextedia S.A. | 7.8 | 0.15 | +11.8 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Haoxi Health Technology Limited over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2021 | 12.8 m | 304,065 | 2.4 % | n/a |
| 2022 | 16.2 m | 244,587 | 1.5 % | +25.8 % |
| 2023 | 28.2 m | 969,752 | 3.4 % | +74.7 % |
| 2024 | 48.5 m | 1.3 m | 2.7 % | +71.9 % |
| 2025 | 32.8 m | 3.9 m | 11.8 % | -32.4 % |
| 2026 | 54.8 m | -9.5 m | -17.4 % | +67.1 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Haoxi Health Technology Limited over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash and investments | 293,511 | 1.2 m | 6.7 m | 8.6 m | 10.9 m |
| Total Debt | 505,399 | 850,060 | 1.2 m | 2.0 m | 1.6 m |
| Net Debt | 211,888 | -353,143 | -5.5 m | -6.6 m | -9.3 m |
| Equity | -1.5 m | 1.6 m | 11.3 m | 17.4 m | 17.9 m |
| Total assets | 542,993 | 4.5 m | 15.5 m | 21.6 m | 21.6 m |
| Operating cash flow | -675,361 | -872,132 | -747,576 | -3.4 m | -2.6 m |
| Investments (capex) | 8,698 | 45,500 | 55,367 | 2.1 m | 3 |
| Free cash-flow | -684,059 | -917,632 | -802,943 | -3.4 m | -2.6 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
Haoxi Health Technology Limited compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Haoxi Health Technology Limited | 1.2 m | n/a | 11.8 % |
| Harte Hanks, Inc. HHS | 29.9 m | n/a | -0.5 % |
| Scienjoy Holding Corporation SJ | 45.6 m | n/a | -47.3 % |
| Anghami Inc. ANGH | 30.5 m | n/a | -90.1 % |
| Dreamland Limited Class A Ordinary Shares TDIC | 352,394 | n/a | 14.0 % |
| Lottery.com Inc. SEGG | 4.0 m | n/a | -3,678.4 % |
| Everbright Digital Holding Limited Ordinary Shares EDHL | 11.3 m | n/a | -120.6 % |
| Alliance Entertainment Holding Corporation AENT | 252 m | 19.0 | 1.4 % |
| TNL Mediagene TNMG | 2.0 m | n/a | -99.0 % |
| Sector median (Nasdaq) | 18.1 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Haoxi Health Technology Limited: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 12/02/2020 | 0.180 USD | 26/02/2020 |
| 23/12/2019 | 13.86 USD | 31/12/2019 |
| 24/12/2018 | 23.92 USD | 31/12/2018 |
| 26/12/2017 | 20.98 USD | 29/12/2017 |
| 23/12/2016 | 15.10 USD | 30/12/2016 |
| 24/12/2015 | 18.78 USD | 31/12/2015 |
| 24/12/2014 | 11.72 USD | 31/12/2014 |
| 24/12/2013 | 10.94 USD | 31/12/2013 |
Stock splits
| Date | Operation |
|---|---|
| 14/08/2026 | reverse split: 1 share for 20 |
| 21/05/2026 | reverse split: 1 share for 128 |
| 27/01/2025 | reverse split: 1 share for 25 |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Haoxi Health Technology Limited.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Haoxi Health Technology Limited
What is the Haoxi Health Technology Limited share price?
Latest recorded price: 2.08 USD on 13/11/2026, for a market cap of 1.2 m USD.
What is the revenue of Haoxi Health Technology Limited?
54.8 m USD for fiscal year 2026, with net income of -9.5 m USD (net margin -17.4 %).
Does Haoxi Health Technology Limited pay a dividend?
Yes. Latest dividend: 0.180 USD per share, ex-dividend on 12/02/2020. Over 12 months: 0.0000 USD. Yield on the latest known price: 0.0 %.
Is Haoxi Health Technology Limited stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN KYG4290F1000).
How many employees does Haoxi Health Technology Limited have?
30 full-time employees according to the latest published profile.
Who runs Haoxi Health Technology Limited?
Zhen Fan is the company's chief executive.